2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-116152
    Cipepofol 1637741-58-2 99.82%
    Cipepofol (Ciprofol), a novel 2,6-disubstituted phenol derivative, is a positive allosteric modulator and direct agonist of the GABAA receptor. Cipepofol can cause the central nerve inhibition and promote sleep based on the structural modification of Propofol (HY-B0649). Cipepofol can activate the sirtuin1 (Sirt1)/Nrf2 pathway. Cipepofol protects the heart against Isoproterenol (ISO; HY-B0468)-induced myocardial infarction by reducing cardiac oxidative stress, inflammatory response and cardiomyocyte apoptosis.
    Cipepofol
  • HY-B0432A
    Propafenone hydrochloride 34183-22-7 98.47%
    Propafenone (hydrochloride) (SA-79 (hydrochloride)) is a class of anti-arrhythmic medication, which treats illnesses associated with rapid heart beats such as atrial and ventricular arrhythmias.
    Propafenone hydrochloride
  • HY-N0504R
    Lovastatin (Standard) 75330-75-5 99.94%
    Lovastatin (Standard) is the analytical standard of Lovastatin. This product is intended for research and analytical applications. Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.
    Lovastatin (Standard)
  • HY-N1428S
    Citric acid-d4 147664-83-3 ≥98.0%
    Citric acid-d4 is the deuterium labeled Citric acid (HY-N1428). Citric acid is a natural preservative and food tartness enhancer. Citric acid induces apoptosis and cell cycle arrest at G2/M phase and S phase in HaCaT cells. Citric acid cause oxidative damage of the liver by means of the decrease of antioxidative enzyme activities. Citric acid is also an acidulant, emulsifier, sequestrant and buffering agent widely used across many industries.
    Citric acid-d4
  • HY-Y0850E
    Polyvinyl alcohol (Mw 30000-70000, 87-90% hydrolyzed) 9002-89-5
    Polyvinyl alcohol (Mw 30000-70000, 87-90% hydrolyzed) is a polyvinyl alcohol with a molecular weight of 30000-70000 and hydrolytic properties. The degree of hydrolysis refers to the degree to which the acetate groups in the original polyvinyl acetate are converted into hydroxyl groups during the hydrolysis process. Polyvinyl alcohol (Mw 30000-70000, 87-90% hydrolyzed) is the hydrolysis and removal of acetate groups after the polymerization of ethylene acetate. And polyvinyl alcohol is obtained. A degree of hydrolysis of 87-90% indicates that a large part of the acetate groups have been removed, resulting in a large number of hydroxyl groups in the PVA structure. Polyvinyl alcohol with different degrees of hydrolysis can be used to self-crosslink to form cryogel, which can be used as biological excipients.
    Polyvinyl alcohol (Mw 30000-70000, 87-90% hydrolyzed)
  • HY-104026S
    L-Kynurenine-d4 2672568-86-2 ≥99.0%
    L-Kynurenine-d4 is the deuterium labeled L-Kynurenine. L-Kynurenine is a metabolite of the amino acid L-tryptophan. L-Kynurenine is an aryl hydrocarbon receptor agonist[1][2].
    L-Kynurenine-d4
  • HY-W592871
    10-Hydroxy-2-decenoic acid 765-01-5 ≥98.0%
    10-Hydroxy-2-decenoic acid (10-HDA) is the major lipid component of royal jelly produced by honeybees. 10-Hydroxy-2-decenoic acid has several health-beneficial effects in mammals, such as antitumor activity, anti-inflammatory activity, and antiangiogenic activity. 10-Hydroxy-2-decenoic acid also extends the lifespan of C. elegans.
    10-Hydroxy-2-decenoic acid
  • HY-14657
    Dantrolene sodium 14663-23-1 ≥98.0%
    Dantrolene sodium is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene sodium is also a calcium channel protein inhibitor. Dantrolene sodium inhibits the release of Ca2+ from RyR1 and RyR3, which can be beneficial in a variety of pathologies caused by disruptions in calcium homeostasis (e.g., stroke, ischemia/reperfusion injury, and neurodegenerative diseases). Dantrolene sodium offers relief of muscle spasms, malignant hyperthermia, and antitoxic, antipyretic, and anti-inflammatory properties.
    Dantrolene sodium
  • HY-40294
    Indazole 271-44-3 ≥98.0%
    Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases.
    Indazole
  • HY-B0358
    Flunarizine 52468-60-7 99.93%
    Flunarizine is a potent dual Na+/Ca2+ channel (T-type) blocker. Flunarizine is a D2 dopamine receptor antagonist. Flunarizine shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects.
    Flunarizine
  • HY-P99031
    Mavrilimumab 1085337-57-0 98.37%
    Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death.
    Mavrilimumab
  • HY-P99590A
    Sotatercept (mIgG2a) 99.71%
    Sotatercept (mIgG2a) has direct cardioprotective actions, which reduces right ventricular (RV) remodeling and improves function in a pulmonary artery banding (PAB) mouse model.
    Sotatercept (mIgG2a)
  • HY-12345
    ML365 947914-18-3 98.62%
    ML365 is a selective two-pore domain potassium channel KCNK3/TASK1 inhibitor, with an IC50 of 4 nM. ML365 acts as a pharmacological tool that can be used to examine the specific roles of TASK1 channels.
    ML365
  • HY-13894
    Tyrphostin AG1296 146535-11-7 99.69%
    Tyrphostin AG1296 is a potent and selective inhibitor of platelet-derived growth factor receptor (PDGFR), with an IC50 of 0.8 μM. Tyrphostin AG1296 inhibits signaling of human PDGF α- and β-receptors as well as of the related stem cell factor receptor (c-Kit). Tyrphostin AG1296 is also a potent inhibitor of FLT3, with an IC50 in the micromolar range.
    Tyrphostin AG1296
  • HY-14914
    Azilsartan 147403-03-0 99.68%
    Azilsartan (TAK-536) is an orally active, potent, selective and specific angiotensin II type 1 receptor (AT1) antagonist. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. Azilsartan can be used for hypertension and stroke research.
    Azilsartan
  • HY-15125
    (R)-(+)-Bay-K-8644 98791-67-4
    (R)-(+)-Bay-K-8644 is a calcium channel inhibitor. (R)-(+)-Bay-K-8644 inhibits Ba2+ currents (IBa) (IC50=975 nM).
    (R)-(+)-Bay-K-8644
  • HY-15849
    LP-533401 945976-43-2 98.68%
    LP-533401 is a Tryptophan hydroxylase 1 inhibitor that regulates serotonin production in the gut.
    LP-533401
  • HY-19307
    SB-273005 205678-31-5 99.94%
    SB-273005 is an orally active non-peptide αvβ3 integrin antagonist with Ki values of 1.2 nM and 0.3 nM for αvβ3 and αvβ5, respectively. SB-273005 blocks the binding of integrins to the RGD sequence in the extracellular matrix. SB-273005 inhibits Rictor phosphorylation and reduces IL-10 secretion. SB-273005 inhibits inflammation, prevents bone loss, regulates vascular smooth muscle function, and reverses pregnancy-induced immune deviation. SB-273005 can be used in the study of rheumatoid arthritis, osteoporosis, and aneurysms. .
    SB-273005
  • HY-19328
    ACY-775 1375466-18-4 99.71%
    ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC50 of 7.5 nM. ACY775 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).
    ACY-775
  • HY-B0079
    Sugammadex sodium 343306-79-6 ≥98.0%
    Sugammadex sodium is a synthetic γ-cyclodextrin derivative, and acts as a reversal agent for neuromuscular block. Sugammadex sodium shows nephroprotective effect in ischemia-reperfusion injury.
    Sugammadex sodium
Cat. No. Product Name / Synonyms Application Reactivity